Key Takeaways
- The Bank of Japan (JPY) maintained its benchmark interest rate at 0.50% but surprised markets by announcing the sale of its ETF and J-REIT holdings, signaling a move towards policy normalization and causing the Japanese Yen to strengthen.
- The European Union approved significant new therapy options, including Merck's (MRK) Enflonsia for RSV prevention in infants and an extended label for Novo Nordisk's (NVO) oral semaglutide (Rybelsus) for cardiovascular benefits in type 2 diabetes.
- Germany's Economy Ministry is actively exploring options for nationalized energy firms SEFE and Uniper, including a potential sale, IPO, or even a merger to create a "German gas giant," driven by an EU mandate to reduce state ownership by 2028.
- Citigroup (C) made notable analyst calls, downgrading Intel (INTC) to "Sell" despite raising its price target to $29 following Nvidia's (NVDA) $5 billion investment, while also increasing its target price for Bank of America (BAC) to $58.
- AstraZeneca's (AZN) Koselugo received EU approval for extended use in adult and pediatric patients with neurofibromatosis type 1 (NF1), expanding its therapeutic reach.
Central Banks and Currency Markets in Focus
The Bank of Japan (BoJ) maintained its benchmark short-term interest rate at 0.50% following a 7-2 vote, aligning with market expectations. However, the central bank surprised investors by announcing it would begin selling its holdings of exchange-traded funds (ETFs) and Japan Real Estate Investment Trusts (J-REITs) at an annual pace of approximately JPY 330 billion and JPY 5 billion, respectively. This unexpected move, seen as a "hawkish twist," led to a notable strengthening of the Japanese Yen (JPY) against the US Dollar (USD).
Meanwhile, US equity futures remained flat, and European bourses were mostly higher as markets absorbed the BoJ's decision and looked ahead to a scheduled call between US President Trump and Chinese President Xi Jinping. Discussions during the call are anticipated to cover the future of TikTok's US operations and broader trade relations, potentially influencing risk assets.
Pharmaceutical Sector Sees Key European Approvals
The European Union's pharmaceutical landscape is experiencing significant developments with multiple new drug approvals. Merck's (MRK) Enflonsia (clesrovimab) received a positive recommendation for marketing authorization from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on September 18, 2025. This approval is for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. Enflonsia stands out as the first RSV preventive for infants to offer a single, fixed 105 mg dose regardless of the child's weight, a key differentiator from existing treatments. This follows its earlier FDA approval in June 2025.
In another significant development, Novo Nordisk's (NVO) oral semaglutide, marketed as Rybelsus, received EU approval for an updated label. The update reflects proven cardiovascular benefits for patients with type 2 diabetes, making it the first and only oral GLP-1 RA to demonstrate a reduction in cardiovascular death, heart attack, and stroke. This approval is based on positive data from the SOUL trial.
Additionally, AstraZeneca’s (AZN) Koselugo (selumetinib) has been approved in Europe for extended use. The EMA's CHMP recommended a change to its marketing authorization to include adult and pediatric patients aged 3 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). This expansion follows successful results from the Phase III KOMET trial, which demonstrated a statistically significant and clinically meaningful objective response rate in adult patients.
German Government Explores Options for Nationalized Energy Firms
The German Economy Ministry has announced it is exploring various strategic options for the nationalized energy companies SEFE (Securing Energy for Europe) and Uniper. These options include a potential sale, an initial public offering (IPO), or even a merger of the two entities to form a "German gas giant." The deliberations are driven by an EU mandate requiring Berlin to reduce its stake in both companies to no more than 25% plus one share by 2028.
Both SEFE and Uniper were nationalized in 2022 to ensure energy supply security during Europe's energy crisis, with SEFE receiving a €6.3 billion bailout and Uniper a €13.5 billion government injection. While the economy ministry is reportedly open to a tie-up, the finance ministry remains more skeptical, viewing a merger as a fallback if independent sales fail.
Analyst Ratings and M&A Activity
Citigroup (C) issued a notable downgrade for Intel (INTC), moving it to "Sell" from "Neutral," despite simultaneously increasing its price target to $29 from $24. This decision follows a recent rally in Intel shares, spurred by Nvidia's (NVDA) announced $5 billion investment and collaboration to jointly develop datacenter and PC chips. Citi analysts expressed skepticism regarding the deal's ability to significantly boost Intel's struggling foundry business. In a separate move, Citigroup also raised its price target on Bank of America (BAC) to $58 from $54, while maintaining a "Buy" rating.
In the private equity space, the European Commission has approved Warburg Pincus's acquisition of a majority stake in Uvex Group. The transaction, announced on July 1, 2025, sees the US-based global private equity fund taking control of the German protective safety and sports equipment company in a deal reportedly valued at approximately €800 million. The founding Winter and Grau families will retain a significant minority stake in the business.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.